Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 May 20:12:661643.
doi: 10.3389/fimmu.2021.661643. eCollection 2021.

Tackling Chronic Kidney Transplant Rejection: Challenges and Promises

Affiliations
Review

Tackling Chronic Kidney Transplant Rejection: Challenges and Promises

Xingqiang Lai et al. Front Immunol. .

Abstract

Despite advances in post-transplant management, the long-term survival rate of kidney grafts and patients has not improved as approximately forty percent of transplants fails within ten years after transplantation. Both immunologic and non-immunologic factors contribute to late allograft loss. Chronic kidney transplant rejection (CKTR) is often clinically silent yet progressive allogeneic immune process that leads to cumulative graft injury, deterioration of graft function. Chronic active T cell mediated rejection (TCMR) and chronic active antibody-mediated rejection (ABMR) are classified as two principal subtypes of CKTR. While significant improvements have been made towards a better understanding of cellular and molecular mechanisms and diagnostic classifications of CKTR, lack of early detection, differential diagnosis and effective therapies continue to pose major challenges for long-term management. Recent development of high throughput cellular and molecular biotechnologies has allowed rapid development of new biomarkers associated with chronic renal injury, which not only provide insight into pathogenesis of chronic rejection but also allow for early detection. In parallel, several novel therapeutic strategies have emerged which may hold great promise for improvement of long-term graft and patient survival. With a brief overview of current understanding of pathogenesis, standard diagnosis and challenges in the context of CKTR, this mini-review aims to provide updates and insights into the latest development of promising novel biomarkers for diagnosis and novel therapeutic interventions to prevent and treat CKTR.

Keywords: IFTA; T cells mediated rejection; biomarkers; chronic allograft rejection; kidney transplant.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Similar articles

Cited by

References

    1. Kasiske BL, Andany MA, Danielson B. A Thirty Percent Chronic Decline in Inverse Serum Creatinine Is an Excellent Predictor of Late Renal Allograft Failure. Am J Kidney Dis (2002) 39:762–8. 10.1053/ajkd.2002.31996 - DOI - PubMed
    1. Hara S. Current Pathological Perspectives on Chronic Rejection in Renal Allografts. Clin Exp Nephrol (2017) 21:943–51. 10.1007/s10157-016-1361-x - DOI - PubMed
    1. Stegall MD, Park WD, Larson TS, Gloor JM, Cornell LD, Sethi S, et al. . The Histology of Solitary Renal Allografts At 1 and 5 Years After Transplantation. Am J Transplant (2011) 11:698–707. 10.1111/j.1600-6143.2010.03312.x - DOI - PubMed
    1. Shiu KY, Stringer D, McLaughlin L, Shaw O, Brookes P, Burton H, et al. . Effect of Optimized Immunosuppression (Including Rituximab) on Anti-Donor Alloresponses in Patients With Chronically Rejecting Renal Allografts. Front Immunol (2020) 11:79. 10.3389/fimmu.2020.00079 - DOI - PMC - PubMed
    1. Loupy A, Haas M, Roufosse C, Naesens M, Adam B, Afrouzian M, et al. . The Banff 2019 Kidney Meeting Report (I): Updates on and Clarification of Criteria for T Cell- and Antibody-Mediated Rejection. Am J Transplant (2020) 20:2318–31. 10.1111/ajt.15898 - DOI - PMC - PubMed